Results 1 to 10 of about 16,304 (256)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia [PDF]

INNOVATIONS in Pharmacy
Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia.
Mohammed Alqahtani, Ahmed Al-jedai, Albert Wertheimer   +2 more
doaj   +2 more sources

Unaware and unpowered: evaluating patient perceptions and preferences of biosimilars in South Korea [PDF]

Frontiers in Pharmacology
ObjectivesBiosimilars offer a promising solution to challenges related to healthcare budget sustainability. However, limited patient awareness and understanding often hinder their timely adoption.
Eunjung Choi, Gyeongseon Shin, SeungJin Bae   +2 more
doaj   +2 more sources

What role for real-world evidence in market access of biosimilars? [PDF]

Frontiers in Pharmacology
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars.
Steven Simoens, Catherine M. Lockhart, Delphine F. Courmier   +2 more
doaj   +2 more sources

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars [PDF]

Biosensors
The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics.
Andrea Di Santo, Edoardo Marrani, Carmen Gallo, Fosca Errante, Valerio Maniscalco, Anna Maria Papini, Gabriele Simonini, Paolo Rovero, Feliciana Real Fernandez   +8 more
doaj   +2 more sources

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China [PDF]

Frontiers in Public Health
BackgroundAs China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern.
Xin Du, Xingxian Luo, Qixiang Guo, Qixiang Guo, Xiaomeng Jiang, Xiaomeng Jiang, Ziling Su, Weiting Zhou, Zhongjian Wang, Jiarun Li, Yue Yang, Yue Yang, Yi Zhang   +12 more
doaj   +2 more sources

Biosimilars [PDF]

ESMO Open, 2018
Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
  +11 more sources

Biosimilars in rheumatoid arthritis in 2022 – data from the Romanian Registry of Rheumatic Diseases [PDF]

Romanian Journal of Rheumatology, 2023
Objective. The study aimed at determining whether RA patients starting or stopping biosimilars differ in any regard from those starting or stopping originals. Methods.
Horatiu Popoviciu, Florentin Vreju, Claudiu C. Popescu, Corina Mogosan, Elena Rezus, Simona Rednic, Andra Balanescu, Razvan Adrian Ionescu, Catalin Codreanu   +8 more
doaj   +1 more source

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey

Frontiers in Pharmacology, 2022
Objective: With increasing numbers of biosimilars entering the market or in the approval pipeline in China, understanding the current awareness and attitudes of biosimilars still remains the first step to promote uptake.
Yang Hu, Yang Hu, Yang Hu, Yang Hu, Zaiwei Song, Zaiwei Song, Zaiwei Song, Dan Jiang, Dan Jiang, Dan Jiang, Dan Jiang, Lin Zhuo, Yinchu Cheng, Yinchu Cheng, Yinchu Cheng, Rongsheng Zhao, Rongsheng Zhao, Rongsheng Zhao   +17 more
doaj   +1 more source

Biosimilars [PDF]

Arquivos Brasileiros de Endocrinologia & Metabologia, 2011
Although common themes permeate the environment across continents and particular divergences as to how to proceed exist between different regulatory agencies, it seems that policies are still in flux. Not all polices will suffice to fit all dissimilar biologics, and these in place or being developed may, in turn, change to accommodate new or unexpected
openaire   +6 more sources

Biosimilar insulins in international and domestic practice of pharmacist

Фармацевтичний журнал, 2022
In Ukraine, people with diabetes receive insulin, including insulin biosimilars in pharmacies, so pharmacists should increase their knowledge about biosimilar because they become more available in the coming years. The aim of the work was to summarize
I. O. Vlasenko, I. V. Nizhenkovska
doaj   +1 more source